Currently, there are 75.79M common shares owned by the public and among those 73.30M shares have been available to trade.
The company’s stock has a 5-day price change of -0.77% and -10.32% over the past three months. XENE shares are trading -0.74% year to date (YTD), with the 12-month market performance down to -19.04% lower. It has a 12-month low price of $35.53 and touched a high of $50.99 over the same period. XENE has an average intraday trading volume of 410.97K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.64%, -2.52%, and -3.49% respectively.
Institutional ownership of Xenon Pharmaceuticals Inc (NASDAQ: XENE) shares accounts for 97.16% of the company’s 75.79M shares outstanding.
It has a market capitalization of $2.97B and a beta (3y monthly) value of 1.25. The earnings-per-share (ttm) stands at -$2.81. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.53% over the week and 3.27% over the month.
Earnings per share for the fiscal year are expected to decrease by -13.44%, and -20.30% over the next financial year. EPS should shrink at an annualized rate of -14.82% over the next five years, compared to -10.87% over the past 5-year period.
Looking at the support for the XENE, a number of firms have released research notes about the stock. Deutsche Bank stated their Buy rating for the stock in a research note on February 11, 2025, with the firm’s price target at $67. Raymond James coverage for the Xenon Pharmaceuticals Inc (XENE) stock in a research note released on October 10, 2024 offered a Outperform rating with a price target of $50. H.C. Wainwright was of a view on October 01, 2024 that the stock is Buy, while Citigroup gave the stock Buy rating on January 04, 2024, issuing a price target of $62. Robert W. Baird on their part issued Outperform rating on December 08, 2023.
